So this slide shows multiple value realisation strategies, however all of the dot points talk about licensing, one even making the point that taking products to pH3 and FDA approved is not within the remit of biotech.
So it appears there are not multiple pathways, the pathway/plan is to licence out.
Remember it used to be, to get bought out at end of Ph2 - now it is about licensing.
.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.4¢ | 1.2¢ | $134.2K | 10.31M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1168170 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 9464131 | 33 |
| Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |
Day chart unavailable